Lymphatic malformation
MONDO:0019313Primary lymphedema is caused by anatomic or functional defects in the lymphatic system, resulting in chronic swelling of body parts and lymphatic-system malformation.
Also known as: hereditary lymphedema, lymphedema, hereditary
56 clinical trials for this condition and its sub-types, 17 tagged with Lymphatic malformation itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lymphatic malformation
-
Noonan syndrome 22 trials · 25 incl. sub-types
14 sub-types
- Noonan syndrome 3 2 trials
- Noonan syndrome 5 1 trial
- Noonan syndrome 1 0 trials
- Noonan syndrome 10 0 trials
- Noonan syndrome 11 0 trials
- Noonan syndrome 13 0 trials
- Noonan syndrome 14 0 trials
- Noonan syndrome 2 0 trials
- Noonan syndrome 4 0 trials
- Noonan syndrome 6 0 trials
- Noonan syndrome 7 0 trials
- Noonan syndrome 8 0 trials
- Noonan syndrome 9 0 trials
- Noonan syndrome 12 0 trials
-
Lymphatic malformation 5 8 trials
-
Lymphatic malformation 12 2 trials
-
Dahlberg-Borer-Newcomer syndrome 0 trials
-
Hennekam syndrome 0 trials
3 sub-types
-
Norman-Roberts syndrome 0 trials
-
Campomelia, Cumming type 0 trials
-
Lymphatic malformation 1 0 trials
-
Lymphatic malformation 10 0 trials
-
Lymphatic malformation 11 0 trials
-
Lymphatic malformation 13 0 trials
-
Lymphatic malformation 14 0 trials
-
Lymphatic malformation 2 0 trials
-
Lymphatic malformation 3 0 trials
-
Lymphatic malformation 4 0 trials
-
Lymphatic malformation 6 0 trials
-
Lymphatic malformation 7 0 trials
-
Lymphatic malformation 8 0 trials
-
Lymphatic malformation 9 0 trials
-
Lymphedema-distichiasis syndrome 0 trials
-
Yellow nail syndrome 0 trials
-
New pill could shrink abnormal vessels in rare childhood disorders
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called KP-001 in 150 people aged 2 and older with venous malformations, lymphatic malformations, or KTS/CLOVES syndrome. Participants receive either KP-001 or a placebo for 24 weeks, then everyone gets the drug for another 28 weeks. The goal …
Phase 3 • Sponsor: Kaken Pharmaceutical • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
New drug trial aims to shrink painful lymphatic growths in kids and adults
Disease control Recruiting nowThis study tests alpelisib, a drug that targets a specific gene mutation (PIK3CA), in people with lymphatic malformations—abnormal growths of lymph vessels. The trial includes children and adults and compares alpelisib to a placebo to see if it can shrink the growths and ease sym…
Phase 2/3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis Phase 2 study tests an oral drug called RLY-2608 in adults and children with overgrowth conditions (like CLOVES or Klippel-Trenaunay syndrome) caused by PIK3CA gene mutations. The drug is designed to block the faulty protein driving abnormal tissue growth. The trial will enr…
Phase 2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New injection could help kids with rare growths avoid major surgery
Disease control Recruiting nowThis study tests an injected medicine called TARA-002 for children aged 6 months to 18 years who have lymphatic malformations (fluid-filled cysts). The goal is to see if the injections can safely shrink or eliminate the cysts. Up to 38 children will receive up to 4 injections, ea…
Phase 2 • Sponsor: Protara Therapeutics • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Could a common drug shrink rare growths in Kids' faces and necks?
Disease control Recruiting nowThis study tests whether the drug rapamycin can shrink large, hard-to-treat lymphatic malformations in the head and neck area of children. Over 6 months, 28 kids will take oral rapamycin, and doctors will measure changes using MRI scans and quality-of-life surveys. The goal is to…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for rare vascular malformations: targeted drugs enter trial
Disease control Recruiting nowThis phase 2 trial is testing two targeted drugs—alpelisib and mirdametinib—in 50 people with slow-flow or fast-flow vascular malformations that haven't responded to standard treatments. The goal is to see if these drugs can improve each person's most bothersome symptom over 48 w…
Phase 2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Weekly pill could tame painful birthmarks with fewer side effects
Disease control Recruiting nowThis study tests whether taking the drug sirolimus just once a week can safely treat venous and lymphatic malformations—abnormal clusters of blood vessels or lymph vessels that can cause pain and swelling. Current daily dosing works but often causes side effects like low white bl…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Glow-in-the-Dark dye could make Children's tumor surgery safer and more effective
Disease control Recruiting nowThis study tests whether a special dye (indocyanine green) that glows under a special camera can help surgeons better see and remove cystic lymphatic malformations in children. About 110 children will be randomly assigned to either standard surgery or surgery guided by this dye. …
Sponsor: Nanjing Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for kids with rare eye condition: drug combo shows promise
Disease control Recruiting nowThis study tests a systematic approach for treating orbital lymphatic malformation in children aged 1-18. Participants are split into three groups: one gets sclerotherapy (injections to shrink the lesion), one gets the drug sirolimus, and one gets both. The goal is to see if siro…
Phase 3 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Scientists launch global effort to unravel mysteries of rare lymphatic diseases
Knowledge-focused Recruiting nowThis study is creating a registry of up to 1,000 people with rare lymphatic system disorders. Researchers will collect information from medical records and yearly surveys to understand how these diseases progress, what treatments are used, and how they affect quality of life. The…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Massive study launches to unravel mysteries of rare lymphatic diseases
Knowledge-focused Recruiting nowThis natural history study aims to collect data from 1,200 people with lymphatic anomalies—rare conditions affecting the body's lymph system—over many years. Researchers will track symptoms, perform genetic testing, and gather biospecimens to better understand why these condition…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC